Journal
MOLECULAR CANCER THERAPEUTICS
Volume 12, Issue 9, Pages 1805-1815Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-12-1007
Keywords
-
Categories
Funding
- Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH
Ask authors/readers for more resources
The epithelial-mesenchymal transition (EMT) is a process associated with the metastasis of solid tumors as well as with the acquisition of resistance to standard anticancer modalities. A major initiator of EMT in carcinoma cells is TGF-beta, which has been shown to induce the expression of several transcription factors ultimately responsible for initiating and maintaining the EMT program. We have previously identified Brachyury, a T-box transcription factor, as an inducer of mesenchymal features in human carcinoma cells. In this study, a potential link between Brachyury and TGF-beta signaling has been investigated. The results show for the first time that Brachyury expression is enhanced during TGF-beta 1-induced EMT in various human cancer cell lines, and that a positive feedback loop is established between Brachyury and TGF-beta 1 in mesenchymal-like tumor cells. In this context, Brachyury overexpression is shown to promote upregulation of TGF-beta 1 at the mRNA and protein levels, an effect mediated by activation of the TGF-beta 1 promoter in the presence of high levels of Brachyury. Furthermore, inhibition of TGF-beta 1 signaling by a small-molecule inhibitor of TGF-beta receptor type I decreases Brachyury expression, induces a mesenchymal-to-epithelial transition, and renders cancer cells more susceptible to chemotherapy. This study thus has implications for the future development of clinical trials using TGF-beta inhibitors in combination with other anticancer agents. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available